FDA approves zenocutuzumab for advanced non-small-cell lung cancer and pancreatic cancer with NRG1 fusion, offering new hope for aggressive cancers.

On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic...

On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic...

The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing...

uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's...

Radiopharmaceutical medical imaging manufacturer Cyclopharm has revealed a possible new use for its Technegas system – for evaluating the progress...

The Food and Drug Administration (FDA) is reviewing a petition to ban red dye No. 3, a common additive in beverages, snacks, cereals, and candies. Jim...

WEDNESDAY, Dec. 18, 2024 -- The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic...

WEDNESDAY, Dec. 18, 2024 -- The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic...

The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell...